Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-01

Study Completion Date

2025-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This two-phase project seeks to examine the cardiovascular response to consumption of cannabis variants of different cannabinoid composition through different methods (smoking vs. vaporizing), at rest and during aerobic exercise. Multiple measures that have been shown to predict risk factors for chronic-disease and negative health outcomes will be assessed following cannabis consumption at rest or in combination with exercise. These techniques will examine arterial stiffness, vascular function, and cardiac function. In phase I and II, subjects will visit the lab on 6 different occasions; with 1 visit acting as an introductory visit, 1 as an exercise control visit, 2 as resting cannabis visits, and 2 as cannabis + exercise visits. Cannabis used in phase I of this study will consist of approximately 10% THC. On all visits, pulse wave velocity, flow mediated dilation, and echocardiography measures will be performed following cannabis consumption by smoking or vaporizing, and cannabis consumption by smoking or vaporizing followed by 20 minutes of exercise on a cycle ergometer. Phase II of the study will implore a similar design. In favor of altering method of consumption, in all visits cannabis will be consumed by vaporization and will be either a high cannabidiol (CBD: (\~10%)) and low delta-9-tetrahydrocannabinol (THC: (\<1%)), or a high THC (\~10%) and low CBD (\<1%) variant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Processing and Effects of Cannabis

NCT00225407

Hypotension Tachycardia

UNKNOWN PHASE1

Studying the Effects of Cannabis on Vasculature

NCT05581368

Cardiovascular Diseases Inflammation Atherosclerosis

RECRUITING

Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels

NCT02019680

Abnormalities Hyperlipidemia Cardiovascular Disease +1 more

WITHDRAWN

Health Condition of Cannabis Consumers in the Canadian Population

NCT03987347

Cannabis Use Old Age Health Risk

WITHDRAWN

A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users

NCT05320367

Cannabis

NOT_YET_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Cardiovascular Risk Factor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked.

Intervention Type DRUG

Cannabis

Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized.

Intervention Type DRUG

Cannabis

Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked.

Intervention Type DRUG

Cannabis

Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

High THC, Smoked High THC, Vaporized High CBD, Smoked High CBD, Vaporized

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provision of signed and dated informed consent form
2. Stated willingness to comply with all study procedures and availability for the duration of the study
3. Male or female, aged 19-45yr
4. In good general health as evidenced by medical history and free of chronic disease
5. Must be experienced with cannabis use. This requires recreational cannabis use of a minimum of once per week in the past 30 days as confirmed by urine test
6. Experience consuming cannabis recreationally by vaping dried cannabis

Exclusion Criteria

1. Deemed unfit to exercise by the PARQ+.
2. Current or past diagnoses of substance abuse disorder
3. Failure of recreational substance urine screening test
4. Current, past, or strong family history of psychosis, or has previously experienced a cannabis-related psychotic episode
5. Current or past diagnoses of cannabis use disorder
6. Current or past diagnoses of any mood or anxiety disorder
7. Identified ECG abnormalities
8. Systolic blood pressure exceeding 160mmHg
9. Diastolic blood pressure exceeding 90mmHg
10. Resting heart rate exceeding 100bpm, or lower than 40bpm
11. Diagnosed with respiratory disease
12. Diagnosed with cardiovascular disease
13. Diagnosed with liver disease
14. Diagnosed with kidney disease
15. Is Pregnant or planning to be pregnant
16. Currently taking prescription medication (excluding contraceptive medication)
17. Is a cigarette smoker

Minimum Eligible Age

19 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes